Use of recombinant human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma

Journal of the American Animal Hospital Association

Volumn 44, Issue 5, 2008, Pages 276-282

  Tzannes, Sophia ^a   Ibarrola, Patricia ^a   Batchelor, Daniel J ^a   Burrow, Rachel D ^a   Blackwood, Laura ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; DOG; DOG DISEASE; FATALITY; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; PATHOLOGY; REMISSION; SKIN TUMOR; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FATAL OUTCOME; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2A; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 58149109735     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0440276     Document Type: Article

References (47)

1. Brown NO, Nesbitt GH, Patanaik AK, et al. Cutaneous lymphosarcorna in the dog: a disease with variable clinical and histological manifestations. J Am Anim Hosp Assoc 1980;16:565-572.
2. Moore PF, Olivry T, Naydan D. Canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD+8 T cells. Am J Path 1994;144:421-429.
3. Flournel-Fleury C, Ponce F, Feldman P, et al. Canine T-cell lymphomas: a morphological, immunological and clinical study of 46 new cases. Vet Pathol 2002;39:92-109.
4. Vail DM, MacEwan EG, Young KM. B. Canine lymphoma and lymphoid leukaemias. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology. 3rd ed. Philadelphia: WB Saunders, 2001: 558-590.
5. Bunn PA Jr, Koon FA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-487.
6. Day MJ. Immunophenotypic characteristics of cutaneous lymphoid neoplasia in the dog and cat. J Comp Path 1995;112:79-96.
7. Muller GH, Kirk RW, Scott DW. Cutaneous lymphosarcoma. In: Muller GH, Kirk RW, Scott DW, eds. Small Animal Dermatology. 4th ed. Philadelphia: WB Saunders, 1989:918-927.
8. Thrall MA, Macy DW, Synder SP, et al. Cutaneous lymphosarcoma, and leukaemia in a dog resembling Sézary's syndrome in man. Vet Pathol 1984;21:182-186.
9. DeBoer DJ, Turrel JM, Moore PF. Mycosis fungoides in a dog: demonstration of T-cell specificity and response to radiotherapy. J Am Anim Hosp Assoc 1990;26:566-572.
10. Foster AP, Evans E, Kerlin RL, et al. Cutaneous T-cell lymphoma with Sézary syndrome in a dog. Vet Clin Pathol 1997;26:188-192.
11. Magnol JP, Ghernati I, Marchal T, et al. Clinical, morphological and immunophenotypic data based on 10 cases of canine mucocutaneous epidermotropic T-lymphoma (analogous to mycosis fungoides). Importance of an animal model of spontaneous pathology. Bull Acad Nat Med 1996;180:449-462.
12. Couto CG. Cutaneous lymphosarcoma. 11th Proceed Kal Kan Sympos, 1987:17-77.
13. Iwamoto KS, Bennett LR, Norman A, et al. Linoleate produces remission in canine mycosis fungoides. Cancer 1992;(Letter)64:17.
14. Moriello KA, MacEwan EG, Schultz KT. PEG-asparaginase in the treatment of canine epitheliotropic lymphoma and histiocytic proliferative dermatitis. In: Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology. New York: Pergamon Press, 1993: 293-300.
15. Graham JC, Myers RK. Pilot study on the use of lomustine (CCNU) for the treatment of cutaneous lymphoma in dogs. 17th Proceed Ann Intern Med Forum 1999:723.
16. MacDonald JM. Nasal depigmentation. In: Griffin CE, Kwochka KW, MacDonald JM, eds. Current Veterinary Dermatology. St. Louis: Mosby Yearbook, 1993:223-233.
17. White SD, Rosychuk RAW, Scott KW, et al. Use of isoretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc 1993;202:387-391.
18. Williams LE, Rassnick KM, Power H, et al. CCNU for the treatment of epitheliotropic lymphoma in dogs. J Vet Intern Med 2006;20:136-143.
19. Blackwood L. Tumors of the skin: multifocal neoplastic skin diseases. In: Dobson JM, Lascelles BDX, eds. British Small Animal Veterinary Association Manual of Canine and Feline Oncology. 2nd ed. Gloucester: British Small Animal Veterinary Association, 2003:168-178.
20. Vail DM. Tumors of the haematopoietic system: lymphoproliferative and myeloproliferative disorders. In: Dobson JM, Lascelles BDY, eds. British Small Animal Veterinary Association Manual of Canine and Feline Oncology. 2nd ed. Gloucester: British Small Animal Veterinary Association, 2003:276-292.
21. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy 2003;16:311-321.
22. Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 2002;27:578-584.
23. Tamm I, Jasry BR, Pfeffer LM. Antiproliferative action of interferons. In: Pfeffer LM, ed. Mechanisms of Interferon Action. Florida: CRC Press, 1987:25-58.
24. Mossman TF, Cherwinski H, Bond MW, et al. Two types of murine helper T clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
25. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood 1996;88:413-416.
26. Suchin KR, Cassin M, Gottlieb E, et al. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alpha and interleukin 12. J Am Acad Dermatol 2001;44:28-32.
27. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Haematol Oncol Clin North Am 1995;9:997-1010.
28. Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987;317:940-945.
29. Krakowka S, Cummins JM, Ringer SS. The effects of human interferon-alpha upon in vitro canine immune, responses. Vet Immunol Immunopathol. 1988;19:185-196.
30. de Mari K, Maynard L, Eun HM, et al. Treatment of canine parvovirus entefitis with interferon-omega in a placebo-controlled field trial. Vet Rec 2003;152:105-108.
31. Gilger BC, Rose PD, Davidson MG, et al. Low-dose oral administration of interferon-for the treatment of immune-mediated kerato-conjunctivitis sicca in dogs. J Interferon Cytokine Res 1999;19:901-905.
32. Stokking LB, Ehrhart EJ, Lichtensteiger CA, et al. Pigmented epidermal plaques in three dogs. J Am Anim Hosp Assoc 2004;40:411-417.
33. Thompson LA, Grieshaber TL, Glickman L, et al. Human recombinant interferon alpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study. Vet Ther 2004;5:75-81.
34. Cave TA, Gault EA, Argyle DJ. Feline epitheliotropic T-cell lym-phoma with paraneoplastic eosinophilia-immunochemotherapy with vinblastine and human recombinant interferon 2b. Veterinary and Comparative Oncology 2004;2:91-97.
35. White SD. Newly introduced drugs in veterinary dermatology. Proceed 3rd World Congress of Veterinary Dermatology, Edinburgh, 1996:84-87.
36. Cotter SM, Goldstein MA. Treatment of lymphoma and leukaemia with cyclophosphamide, vincristine and prednisolone, I: treatment of dog. J Am Anim Hosp Assot 1983;19:159-165.
37. Beale K, Bolon B. Canine cutaneous lymphosarcoma: epitheliotropic and non-epitheliotropic, a retrospective study. In: Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology. Oxford: Pergamon Press, 1993:273-284.
38. Prescott DM, Gordon J. Personal communication, 2006.
39. Rajan GP, Siefert B, Prümmer O, et al. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch Dermatol Res 1996;288:543-548.
40. Vegna ML, Papa G, Defazio D, et al. Interferon alpha-2a in cutaneous T-cell lymphoma. Eur J Haematol 1990(Suppl);52:32-35.
41. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Haematol Oncol Clin North Am 1995;9:1089-1107.
42. Zeidner NS, Myles MH, Mathiason-Dubard CK, et al. Alpha inter-feron (2b) in combination with zidovudine for the treatment of presymptomatic feline leukaemia virus-induced immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 1990;24:1749-1756.
43. Steis RG, Smith JW II, Urba WJ, et al. Resistance to recombinant interferon alpha-2a in hairy cell leukaemia associated with neutralizing antibodies. N Engl J Med 1988;318:1409-1413.
44. Kohn EC, Steis RG, Sausville ET, et al. Phase II trial of intermittent high-dose recombinant interferon alpha-2a in mycosis fungcides and the Sezary syndrome. J Clin Oncol 1990;8:155-160.
45. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:395-407.
46. Papa G, Tura S, Mandelli F, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991;79(Suppl 1):48-51.
47. Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-2a alone and in combination with etretinate. Br J Dermatol 1988;18:811-818.